We are an in-person clinic in Hertford, UK
India Research has demonstrated that Tesamorelin, in particular, targets visceral fat reduction, while Ipamorelin and CJC-1295 No DAC enhance lipolysis
A randomized controlled trial of semaglutide in 320 persons with NASH (with or without T2D) showed that subcutaneous semaglutide led to a significantly higher proportion of persons with the resolution of NASH than the placebo group, with no statistically significant difference in the improvement of fibrosis stage [12]
From deep visceral fat loss to improved sleep, cognitive sharpness, and lean muscle preservation, the potential is huge
Replication in a larger sample, especially for the nominal associations, would be worthwhile
And I honestly just kind of got all tangled up in that and then lost track of my-my field biologist dreams and just started to get into, you know, real-real hard science